p21活化激酶4在多发性骨髓瘤中的功能作用及治疗靶向
研究评估p21活化激酶4(PAK4)在多发性骨髓瘤(MM)中的生物学功能及治疗潜力。PAK4通过激活MEK-细胞外信号调节激酶通路促进MM细胞生长与存活;口服生物可利用的PAK4变构调节剂KPT-9274在多种MM细胞系及原代MM细胞中显著影响细胞生长与存活,并鉴定FGFR3为PAK4新结合伙伴,KPT-9274对t(4;14)阳性MM细胞有显著活性。
要点
- PAK4通过激活MEK-ERK通路促进多发性骨髓瘤细胞生长与存活。
- KPT-9274在MM细胞系和原代MM细胞中显著影响细胞生长与存活。
- KPT-9274对t(4;14)阳性MM细胞显示显著活性。
核心结论
- PAK4在多发性骨髓瘤中作为癌基因发挥作用,为PAK4调节剂的临床评估提供了依据。
研究设计与样本
- 研究评估PAK4在多发性骨髓瘤中的生物学和功能作用及其作为新治疗靶点的潜力。
主要发现
- PAK4通过激活包括MEK-细胞外信号调节激酶通路在内的MM存活信号通路促进MM细胞生长与存活。
- 口服生物可利用的PAK4变构调节剂KPT-9274在大量MM细胞系和原代MM细胞中,无论单独或存在骨髓微环境时,均显著影响MM细胞生长与存活。
- 研究鉴定FGFR3为PAK4的新结合伙伴,并观察到KPT-9274对t(4;14)阳性MM细胞有显著活性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dysregulated oncogenic serine/threonine kinases play a pathological role in diverse forms of malignancies, including multiple myeloma (MM), and thus represent potential therapeutic targets. Here, we evaluated the biological and functional role of p21-activated kinase 4 (PAK4) and its potential as a new target in MM for clinical applications. PAK4 promoted MM cell growth and survival via activation of MM survival signaling pathways, including the MEK-extracellular signal-regulated kinase pathway. Furthermore, treatment with orally bioavailable PAK4 allosteric modulator (KPT-9274) significantly impacted MM cell growth and survival in a large panel of MM cell lines and primary MM cells alone and in the presence of bone marrow microenvironment. Intriguingly, we have identified FGFR3 as a novel binding partner of PAK4 and observed significant activity of KPT-9274 against t(4;14)-positive MM cells. This set of data supports PAK4 as an oncogene in myeloma and provide the rationale for the clinical evaluation of PAK4 modulator in myeloma.
引用
- Fulciniti M, Martinez-Lopez J, Senapedis W, et al. Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma. Blood. 2017. PMID: 28096095. doi:10.1182/blood-2016-06-724831
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。